Neuralstem

Neuralstem plans reorganization

Friday, May 20, 2016

Neuralstem, a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced a corporate reorganization to further align the company’s resources on advancing the NSI-189 neurogenic small molecule program, currently in a phase II clinical trial for the treatment of major depressive disorder, and to continue to pursue collaborations for the NSI-566 stem cell therapy program that will expedite clinical development.

[Read More]

Nerualstem completes phase Ia MDD trial

Thursday, October 27, 2011

Neuralstem has completed phase Ia in the ongoing safety trial to test its neuroregenerative small molecule drug, NSI-189, in the treatment of major depressive disorder (MDD).  Phase Ia tested the drug in healthy volunteers for safety and tolerability. Phase Ib, which the company expects to commence later this year, will test the safety and tolerability of NSI-189 in depressed patients.

[Read More]